Drugs / 18 F-FP-DTBZ
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT02236754 | Jul 2013 → Apr 2014 | type 1 diabetes mellitus | Columbia University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [(18)F]FP-(+)-DTBZ | “The vesicular monoamine transporter, type 2 (VMAT2) is expressed by insulin producing β cells and was evaluated as a biomarker of β cell mass (BCM) by positron emission...” PMID 26370678 ↗ Sep 2015 |
| Known as | [(18)F]fluoropropyl-dihydrotetrabenazine | “The vesicular monoamine transporter, type 2 (VMAT2) is expressed by insulin producing β cells and was evaluated as a biomarker of β cell mass (BCM) by positron emission...” PMID 26370678 ↗ Sep 2015 |
| Modality | Diagnostic / imaging agent | “The PET radiopharmaceutical 18 F-fluoropropyl(FP)-dihydrotetrabenazine(DTBZ) has been used previously in human subjects without adverse effects.” NCT02236754 ↗ |
| Route | Intravenous | “Subjects will receive a single i.v. administration of no more than 7.6 millicuries (mCi) of \[18 F\]-FP-DTBZ for injection immediately prior to imaging.” NCT02236754 ↗ |